Paweł Hrycaj

A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study

Dae‐Hyun Yoo, Paweł Hrycaj, Pedro C. Miranda et al. · Annals of the Rheumatic Diseases · 2013 · 653 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study

Won Park, Paweł Hrycaj, Volodymyr Kovalenko et al. · Annals of the Rheumatic Diseases · 2013 · 604 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial

Roy Fleischmann, Eduardo Mysler, Stephen Hall et al. · The Lancet · 2017 · 496 citations

Medicine, Pharmacology, Pharmacotherapy +12

Sarilumab and Nonbiologic Disease‐Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors

Roy Fleischmann, Janet van Adelsberg, Yong Lin et al. · Arthritis & Rheumatology · 2016 · 210 citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +17

The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis

Kevin Winthrop, Joel C. Silverfield, Arthur Racewicz et al. · Annals of the Rheumatic Diseases · 2015 · 195 citations · Full text

Veterinary Medicine, Immunology, Pharmacotherapy +17